Lilly's medical team posted the latest TRIUMPH-1 trial data on retatrutide, its triple hormone receptor agonist being tested as an obesity treatment.
Recap by typeshit. Post by @LillyMedical on X.
2:21
The Las Vegas station covers Lilly's experimental retatrutide and why researchers see it as a potential step up in weight loss.
Function Health points out that the body produces GLP-1 itself and lists ways it says can boost it. The claims are the company's own.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
32:59
Tatem discusses tesamorelin and his view that it can reshape the body without moving the scale. Treat the claims as his own, not settled fact.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
He points out 7.9% quit the 12 mg dose over side effects versus 2.7% on Ozempic, a 5.2 point gap, and flags more skin sensation complaints.
Loading…